[{"arm_notes": "", "treatment_id": null, "treatment_name": "Vaccine Candidate AbdalaGroup I (Experimental): (RBD 25 mcg + aluminum hydroxide 0;30 mg)/0;5 mL; by intramuscular route in the deltoid region; schedule 0-14-28 daysGroup II (Experimental): (RBD 50 mcg + aluminum hydroxide de 0;30 mg)/0;5 mL or by intramuscular route in the deltoid region; schedule 0-14-28 days;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;Vaccine candidate Abdala", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (Experimental): (RBD 25 mcg + aluminum hydroxide 0;30 mg)/0;5 mL; by intramuscular route in the deltoid region; schedule 0-14-28 days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Experimental): (RBD 50 mcg + aluminum hydroxide de 0;30 mg)/0;5 mL or by intramuscular route in the deltoid region; schedule 0-14-28 days;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;Vaccine candidate Abdala", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "RBD 25 mcg + aluminum hydroxide 0,30 mg)/0,5 mL;3;Days0-14-28;IM\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "RBD 50 mcg + aluminum hydroxide 0,30 mg)/0,5 mL;3;Days0-14-28;IM\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]